Lupin's Inhalation Research Centre receives EIR from USFDA

Lupin Limited today announced the receipt of an establishment inspection report (EIR) from USFDA for its Inhalation Research Center situated at Coral Springs, Florida. The facility was inspected by USFDA on behalf of UK Medicines and Healthcare Products Regulatory Agency (MHRA) for Lupin’s generic Fostair application to UK MHRA.

Lupin’s Inhalation Research Center focusses on research and development of respiratory products for the treatment of asthma, chronic obstructive pulmonary diseases and other respiratory ailments.

Lupin is a transnational pharmaceutical company headquartered in Mumbai, India. The company develops and commercialises a wide range of branded and generic formulations, biotechnology products and APIs in over 100 markets in US, India and several others.

The company enjoys leadership position in the cardiovascular, anti-diabetic and respiratory segments and has a significant presence in the anti-infective, gastro-intestinal (GI), central nervous system (CNS) and women’s health areas. Lupin is one of the largest pharmaceutical companies in US by prescriptions and in India, by global revenues. The company invests 9.6 per cent of its revenues on research and development.

Lupin has 15 manufacturing sites and seven research centres globally.

The stock of Lupin closed at 560.10, up by 2.39 per cent or Rs 13.10 per share. The intraday high is Rs 573.65 and intraday low is Rs 536.80. The 52-week high is Rs 882.15 and 52-week low is Rs 505 on BSE.